Nanotechnology-Driven Drug Delivery: A Comprehensive Review of Current Trends and Future Directions

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume :15 | Issue : 01 | Page : –
By
vector

Mehak Khanum,

vector

Jennifer.S,

vector

Zaid khan,

  1. Research Scholar, Department of Pharmaceutics, Faculty of Pharmacy, St Jhon’s Pharmacy College, Bangalore, India
  2. Research Scholar, Department of Pharmaceutics, Faculty of Pharmacy, St Jhon’s Pharmacy College, Bangalore, India
  3. Research Scholar, Department of Pharmacy Practice, Faculty of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, India

Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_131049’);});Edit Abstract & Keyword

Nanotechnology has revolutionized drug delivery systems, offering profound advancements in precision, efficiency, and targeted therapeutic interventions. This review examines the revolutionary influence of nanotechnology on medical therapies, focusing on advancements such as precise drug delivery, improved solubility, and responsive treatment systems. These advancements have significantly improved treatment efficacy and minimized side effects, particularly in oncology and chronic disease management. The development of nanoparticles designed for specific cell targeting and environmental responsiveness has been pivotal in enhancing therapeutic outcomes. Although significant progress has been made, obstacles like biocompatibility, scalable manufacturing, and regulatory challenges persist.. Future advancements will depend on addressing these issues, with ongoing research needed to enhance nanoparticle targeting, ensure safety, and streamline production. The integration of AI and nanorobotics presents promising opportunities for optimizing treatment precision and personalization. Bridging the gap between research and clinical application through improved preclinical models, adaptive regulatory frameworks, and global collaborations will be essential in realizing the full potential of nanotechnology for more effective and personalized medical treatments.

Keywords: Nanotechnology, Drug Delivery Systems, Targeted Drug Delivery, Nanoparticles, Regulatory Challenges, AI-Driven Systems, FDA-Approved Nanomedicines.

[This article belongs to Journal of Nanoscience, NanoEngineering & Applications (jonsnea)]

How to cite this article:
Mehak Khanum, Jennifer.S, Zaid khan. Nanotechnology-Driven Drug Delivery: A Comprehensive Review of Current Trends and Future Directions. Journal of Nanoscience, NanoEngineering & Applications. 2025; 15(01):-.
How to cite this URL:
Mehak Khanum, Jennifer.S, Zaid khan. Nanotechnology-Driven Drug Delivery: A Comprehensive Review of Current Trends and Future Directions. Journal of Nanoscience, NanoEngineering & Applications. 2025; 15(01):-. Available from: https://journals.stmjournals.com/jonsnea/article=2025/view=0

References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_131049’);});Edit

  1. Nikam A, Patil A, Magdum C. Nanotechnology: Overview and its application. Asian J Pharm Technol. 2021;11(4):293-5.
  2. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
  3. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1-12.
  4. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6(4):400.
  5. Arora S, Murmu G, Mukherjee K, Saha S, Maity D. A comprehensive overview of nanotechnology in sustainable agriculture. J Biotechnol. 2022 Aug 20;355:21-41.
  6. Nikam A, Patil A, Magdum C. Nanotechnology: Overview and its application. Asian J Pharm Technol. 2021;11(4):293-5.
  7. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6(4):400.
  8. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
  9. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1-12.
  10. Arora S, Murmu G, Mukherjee K, Saha S, Maity D. A comprehensive overview of nanotechnology in sustainable agriculture. J Biotechnol. 2022 Aug 20;355:21-41.Nikam A, Patil A, Magdum C. Nanotechnology: Overview and its application. Asian Journal of Pharmacy and Technology. 2021;11(4):293-5.
  11. Fissell WH. What is nanotechnology? Adv Chronic Kidney Dis. 2013 Nov 1;20(6):452-3.
  12. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: A review of the pharmacist’s role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268-82.
  13. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1-12.
  14. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
  15. Gondim BL, da Silva Catarino J, de Sousa MA, de Oliveira Silva M, Lemes MR, de Carvalho-Costa TM, et al. Nanoparticle-mediated drug delivery: Blood-brain barrier as the main obstacle to treating infectious diseases in CNS. Curr Pharm Des. 2019 Oct 1;25(37):3983-96.
  16. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014;55(4):281-6.
  17. Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci. 2022 Apr 9;23(8):4153.
  18. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, et al. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int J Nanomedicine. 2021 Aug 25:5811-29.
  19. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: A review of the pharmacist’s role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268-82.
  20. Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol. 2021 Apr 1;62:102426.
  21. Wakaskar R. Types of nanocarriers–formulation method and applications. J Bioequiv Availab. 2017;9:10000e77.
  22. Bhatia S, Bhatia S. Nanoparticles: Types, classification, characterization, fabrication methods and drug delivery applications. In: Natural polymer drug delivery systems: Nanoparticles, plants, and algae. 2016:33-93.
  23. Ojah AN, Das T. Different types of nanocarriers for targeted treatment of HIV/AIDS. Int J Curr Pharm Res. 2019 Jun 26:66-9.
  24. Ng PQ, Ling LS, Chellian J, Madheswaran T, Panneerselvam J, Kunnath AP, et al. Applications of nanocarriers as drug delivery vehicles for active phytoconstituents. Curr Pharm Des. 2020 Oct 1;26(36):4580-90.
  25. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: A review of the pharmacist’s role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268-82.
  26. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, et al. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int J Nanomedicine. 2021 Aug 25:5811-29.
  27. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y. A review of drug delivery systems based on nanotechnology and green chemistry: Green nanomedicine. Int J Nanomedicine. 2017 Apr 12:2957-78.
  28. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014;55(4):281-6.
  29. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
  30. Kesharwani P, editor. Nanotechnology-based targeted drug delivery systems for lung cancer. Academic Press; 2019 Jan 26.
  31. Güven E. Nanotechnology-based drug delivery systems in orthopedics. Joint diseases and related surgery. 2021 Apr;32(1):267.
  32. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, Xu Y, Shao J, Wang W, Cai Z. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. International Journal of Nanomedicine. 2021 Aug 25:5811-29.
  33. Tang L, Li J, Zhao Q, Pan T, Zhong H, Wang W. Advanced and innovative nano-systems for anticancer targeted drug delivery. Pharmaceutics. 2021 Jul 27;13(8):1151.
  34. Huang X, Ma Y, Li Y, Han F, Lin W. Targeted drug delivery systems for kidney diseases. Frontiers in Bioengineering and Biotechnology. 2021 May 28;9:683247.
  35. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology in personalized medicine. Journal of personalized medicine. 2022 Apr 22;12(5):673.
  36. Herrmann IK, Rösslein M. Personalized medicine: the enabling role of nanotechnology. Nanomedicine. 2016 Jan 1;11(1):1-3.
  37. De Matteis L, Martín-Rapún R, de la Fuente JM. Nanotechnology in personalized medicine: A promising tool for alzheimer’s disease treatment. Current Medicinal Chemistry. 2018 Oct 1;25(35):4602-15.
  38. Ahmad RM, Mohammad M. Towards the use of nanotechnology and pharmacogenomics in personalized medicine.
  39. Marson D, Laurini E, Aulic S, Fermeglia M, Pricl S. Self-assembling Nanotechnology for Cancer Personalized Medicine. Chemical Engineering Transactions. 2019;74:1549-54.
  40. Tang Q, Yu B, Gao L, Cong H, Song N, Lu C. Stimuli responsive nanoparticles for controlled anti-cancer drug release. Current Medicinal Chemistry. 2018 May 1;25(16):1837-66.
  41. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Innovations in drug delivery systems: A review of the pharmacist’s role in enhancing efficacy and patient compliance. World Journal of Advanced Research and Reviews. 2023;20(3):1268-82.
  42. Longo R, Gorrasi G, Guadagno L. Electromagnetically stimuli-responsive nanoparticles-based systems for biomedical applications: Recent advances and future perspectives. Nanomaterials. 2021 Mar 26;11(4):848.
  43. An X, Zhu A, Luo H, Ke H, Chen H, Zhao Y. Rational design of multi-stimuli-responsive nanoparticles for precise cancer therapy. Acs Nano. 2016 Jun 28;10(6):5947-58.
  44. Thomas RG, Surendran SP, Jeong YY. Tumor microenvironment-stimuli responsive nanoparticles for anticancer therapy. Frontiers in Molecular Biosciences. 2020 Dec 18;7:610533.
  45. Chehelgerdi M, Chehelgerdi M, Allela OQ, Pecho RD, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Molecular cancer. 2023 Oct 9;22(1):169.
  46. Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. ACS nano. 2021 Aug 2;15(8):12567-603.
  47. Zhu C, Ji Z, Ma J, Ding Z, Shen J, Wang Q. Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment. Pharmaceutics. 2021 Jun 24;13(7):940.
  48. Alrushaid N, Khan FA, Al-Suhaimi EA, Elaissari A. Nanotechnology in cancer diagnosis and treatment. Pharmaceutics. 2023 Mar 22;15(3):1025.
  49. Tang Q, Yu B, Gao L, Cong H, Song N, Lu C. Stimuli responsive nanoparticles for controlled anti-cancer drug release. Current Medicinal Chemistry. 2018 May 1;25(16):1837-66.
  50. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, Vafa E, Abbasi M, Amani AM, Chelliapan S, Kamyab H. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: Effective nanoparticle‐based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell biochemistry and function. 2023 Jul;41(5):517-41.
  51. Shoaib A, Darraj A, Khan ME, Azmi L, Alalwan A, Alamri O, et al. A nanotechnology-based approach to biosensor application in current diabetes management practices. Nanomaterials. 2023 Feb 26;13(5):867.
  52. Vargas J, García L, Baena Y. Nanotechnology and herbal products: Advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023 Dec 5;13(12):001-14.
  53. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Jul;7(4):548-64.
  54. Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
  55. Itoo AM, Vemula SL, Gupta MT, Giram MV, Kumar SA, Ghosh B, et al. Multifunctional graphene oxide nanoparticles for drug delivery in cancer. J Control Release. 2022 Oct 1;350:26-59.
  56. Moghadam NB, Avatefi M, Karimi M, Mahmoudifard M. Graphene family in cancer therapy: Recent progress in cancer gene/drug delivery applications. J Mater Chem B. 2023;11(12):2568-613.
  57. Liu J, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 2013 Dec 1;9(12):9243-57.
  58. Oliveira AM, Machado M, Silva GA, Bitoque DB, Tavares Ferreira J, Pinto LA, et al. Graphene oxide thin films with drug delivery function. Nanomaterials. 2022 Mar 30;12(7):1149.
  59. Idumah CI. Design, development, and drug delivery applications of graphene polymeric nanocomposites and bionanocomposites. Emerg Mater. 2023 Jun;6(3):777-807.
  60. Mohammad-Jafari K, Naghib SM. 3D Printing of Microfluidic-assisted Liposomes Production for Drug Delivery and Nanobiomedicine: A Review. Curr Med Chem. 2024.
  61. Yang R, Sun H. A Co-Flow Millifluidic Device for Nanoparticle Synthesis. In: Heat Transfer Summer Conference; 2023 Jul 10; Vol. 87165, p. V001T09A003. American Society of Mechanical Engineers.
  62. Sundaram S, Skouras M, Kim DS, van den Heuvel L, Matusik W. Topology optimization and 3D printing of multimaterial magnetic actuators and displays. Sci Adv. 2019 Jul 12;5(7):eaaw1160.
  63. Wang K, Pan W, Liu Z, Wallin TJ, van Dover G, Li S, et al. 3D printing of viscoelastic suspensions via digital light synthesis for tough nanoparticle–elastomer composites. Adv Mater. 2020 Jun;32(25):2001646.
  64. Feng W, Wen Y, Sun S, Li P, Shi S. Reconfigurable All‐Oil Microfluidic Devices by 3D Printing. Small. 2024:2405892.
  65. Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
  66. Vargas J, García L, Baena Y. Nanotechnology and herbal products: Advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023 Dec 5;13(12):001-14.
  67. Itoo AM, Vemula SL, Gupta MT, Giram MV, Kumar SA, Ghosh B, et al. Multifunctional graphene oxide nanoparticles for drug delivery in cancer. J Control Release. 2022 Oct 1;350:26-59.
  68. Moghadam NB, Avatefi M, Karimi M, Mahmoudifard M. Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications. J Mater Chem B. 2023;11(12):2568-613.
  69. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, et al. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: Effective nanoparticle‐based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell Biochem Funct. 2023 Jul;41(5):517-41.
  70. Vargas J, García L, Baena Y. Nanotechnology and herbal products: Advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023 Dec 5;13(12):001-14.Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
  71. Shoaib A, Darraj A, Khan ME, Azmi L, Alalwan A, Alamri O, et al. A nanotechnology-based approach to biosensor application in current diabetes management practices. Nanomaterials. 2023 Feb 26;13(5):867.
  72. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, et al. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: Effective nanoparticle‐based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell Biochem Funct. 2023 Jul;41(5):517-41.
  73. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Jul;7(4):548-64.
  74. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding Next‐Generation Nanomedicines to Europe: Regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
  75. Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Deliv Rev. 2018 Jun 1;131:122-31.
  76. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018 Aug 20;6:360.
  77. Mühlebach S, Borchard G, Yildiz S. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars. Nanomedicine. 2015 Mar;10(4):659-74.
  78. Bhattacharya S, Alkharfy KM, Janardhanan R, Mukhopadhyay D. Nanomedicine: pharmacological perspectives. Nanotechnol Rev. 2012 Jun 1;1(3):235-53.
  79. Bainbridge WS. Social and ethical implications of nanotechnology. In: Springer Handbook of Nanotechnology. 2004:1135.
  80. Patil AS, Parishwad GV, Kale SK, Husainy AS. Modern ethical and societal implications of nanotechnology. EasyChair; 2020 Nov 21.
  81. Khan AS, Agajanian A. Incorporating social and ethical implications of nanotechnology in the engineering and technology curricula. In: 2011 ASEE Annual Conference & Exposition; 2011 Jun 26. p. 22-850.
  82. Schummer J. ‘Societal and ethical implications of nanotechnology’: Meanings, interest groups, and social dynamics. In: Nanotechnology challenges: implications for philosophy, ethics, and society; 2006. p. 413-49.
  83. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
  84. Luo M, Feng Y, Wang T, Guan J. Micro‐/nanorobots at work in active drug delivery. Adv Funct Mater. 2018 Jun;28(25):1706100.
  85. Zhang D, Liu S, Guan J, Mou F. “Motile-targeting” drug delivery platforms based on micro/nanorobots for tumor therapy. Front Bioeng Biotechnol. 2022 Sep 16;10:1002171.
  86. Kim K, Guo J, Liang Z, Fan D. Artificial micro/nanomachines for bioapplications: biochemical delivery and diagnostic sensing. Adv Funct Mater. 2018 Jun;28(25):1705867.
  87. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next‐generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
  88. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
  89. Beech D. Guest editorial: Bridging the gap between laboratory research and clinical practice—Dentists doing dental materials research. J Dent Res. 1992 May;71(5):1266-.
  90. Di Rienzo G. Situating the KTA gap in clinical research: Foregrounding a discontinuity in practices. Front Psychol. 2023 Jan 13;13:1058845.
  91. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
  92. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomater Sci. 2020;8(17):4653-64.
  93. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next‐generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
  94. Millagaha Gedara NI, Xu X, DeLong R, Aryal S, Jaberi-Douraki M. Global trends in cancer nanotechnology: A qualitative scientific mapping using content-based and bibliometric features for machine learning text classification. Cancers. 2021 Sep 1;13(17):4417.
  95. Sadykova A. Today’s key global trends in engineering education: Preparing freshmen for nanotechnology. In: 2015 International Conference on Interactive Collaborative Learning (ICL); 2015 Sep 20. p. 508-10. IEEE.
  96. Zhu Y, Yao Y, Kuang R, Chen Z, Du Z, Qu S. Global research trends of nanotechnology for pain management. Front Bioeng Biotechnol. 2023 Aug 28;11:1249667.
  97. Idamokoro EM, Hosu YS. Global research trends on the use of nanotechnology to boost meat production: A scientometric analysis. Front Res Metr Anal. 2022 Jan 13;6:793853.
  98. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
  99. Bennett‐Woods D. Anticipating the impact of nanoscience and nanotechnology in healthcare. In: Nanoscale: Issues and Perspectives for the Nano Century. 2007 Aug 10. p. 295-314.
  100. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
  101. Khan AS, Agajanian A. Incorporating Social and Ethical Implications of Nanotechnology in the Engineering and Technology Curricula. In2011 ASEE Annual Conference & Exposition 2011 Jun 26 (pp. 22-850).
  102. Millagaha Gedara NI, Xu X, DeLong R, Aryal S, Jaberi-Douraki M. Global trends in cancer nanotechnology: A qualitative scientific mapping using content-based and bibliometric features for machine learning text classification. Cancers. 2021 Sep 1;13(17):4417.
  103. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next‐generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
  104. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016 Oct;33:2373-87.
  105. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomater Sci. 2020;8(17):4653-64.
  106. Yang B, Shi J. Developing new cancer nanomedicines by repurposing old drugs. Angew Chem Int Ed. 2020 Dec 1;59(49):21829-38.
  107. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014 Aug 10;187:133-44.
  108. Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano. 2020 Oct 6;14(10):12281-90.
  109. Kobayashi H, Turkbey B, Watanabe R, Choyke PL. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem. 2014 Dec 17;25(12):2093-100.
  110. Sahakyan N, Haddad A, Richardson S, Forcha-Etieundem V, Christopher L, Alharbi H, Campbell R. Personalized nanoparticles for cancer therapy: a call for greater precision. Anti-Cancer Agents Med Chem. 2017;17(8):1033-39.
  111. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomaterials science. 2020;8(17):4653-64.
  112. Mi P, Cabral H, Kataoka K. Ligand‐installed nanocarriers toward precision therapy. Adv Mater. 2020 Apr;32(13):1902604.
  113. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016 Oct;33:2373-87.
  114. Lorscheider M, Gaudin A, Nakhlé J, Veiman KL, Richard J, Chassaing C. Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Ther Deliv. 2021 Jan 1;12(1):55-76.
  115. Dai L, Liu J, Luo Z, Li M, Cai K. Tumor therapy: targeted drug delivery systems. J Mater Chem B. 2016;4(42):6758-72.
  116. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomater Sci. 2020;8(17):4653-64.
  117. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next‐generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
  118. Sahakyan N, Haddad A, Richardson S, Forcha-Etieundem V, Christopher L, Alharbi H, Campbell R. Personalized nanoparticles for cancer therapy: a call for greater precision. Anti-Cancer Agents Med Chem. 2017 Jul 1;17(8):1033-9.
Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 23/12/2024
Accepted 30/12/2024
Published 04/01/2025
253